OTC : ARGNF

argenx SE

$865 USD

$0 (0.0%)

Volume
1
Average Volume
11
Market Capitalization
$53.79B
P/E Ratio
32.08
Dividend Yield
0.00%
Price Target
Year High
$960.58
Year Low
$547.60
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$5.12
Company Overview

OTC

Karen Massey

Biotechnology

Healthcare

ARGNF

1863

NL

USD

http://www.argen-x.com

31 10 703 8441

04016X101

0001697862

Liquidity Metrics

0.01

5.12

4.89

2.28

0.00

Sales & Valuation

$4.32B

10.61

6.54

49.19

18.00

Profitability

$20.36

$1.34B

32.87%

33.43%

21.66%

16.99%

P/E Metrics

32.08

0.09

0.09

Analyst Price Target & Rating

N/A

0/5

24 Analysts

%

Financial Health Scores

19.51

5/9

$6.49B

$10.03B

$1.62B

$2.06B

Key Metrics (TTM)

$50.64B

9.76

31.89

5.12

21.66%

17.36%

3.15%

2.07%

$288.93

-106 days

Company Executives
Name Title
Achim Plueckebaum Global Head of Digital Technologies
Sandrine Piret-Gerard Chief Commercialization Officer
Karl Gubitz Chief Financial Officer
Timothy Van Hauwermeiren EMBA Co-Founder & Non-Independent Non-Executive Chairman of the Board
Arjen Lemmen Vice President of Corporate Development & Strategy
Filip Borgions Chief Technology Innovation Officer
Hans de Haard Ir Co-Founder & Member of Board Advisors
Marc Schorpion Global Head of Human Resources
Karen Massey Chief Executive Officer & Executive Director
Malini Moorthy General Counsel & Corporate Secretary
Luc Truyen Chief Medical Officer
Andria Wilk Global Head of Quality
Peter Ulrichts Chief Scientific Officer
Poll Results

No votes yet today — be the first to share your view!

About argenx SE (OTC:ARGNF) Stock

argenx SE operates as a biotechnology firm, specializing in the advancement of various therapeutic solutions for autoimmune diseases across the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, and France. The company's flagship investigational therapy is efgartigimod, currently undergoing Phase III clinical trials for conditions including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. Efgartigimod is also in Phase II/III studies for bullous pemphigoid and idiopathic inflammatory myopathy, with a subcutaneous formulation (ENHANZE SC) in preclinical development. Beyond this primary candidate, argenx SE maintains a pipeline of immunology innovations. These encompass cusatuzumab, aimed at hematological ... cancer and high-risk myelodysplastic syndromes; ARGX-119, an antibody designed to target muscle-specific tyrosine kinase; ARGX-117 for severe autoimmune indications; ARGX-118, which addresses airway inflammation; and ARGX-120, another treatment for autoimmune disorders. Furthermore, argenx SE is involved in external collaborations for several product candidates. These include ARGX-115 for cancer treatment, ARGX-112 which targets the interleukin-22 receptor, and ARGX-114, an antibody directed against the MET receptor. The company has forged strategic alliances with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S. It also maintains an extensive network of collaboration and licensing agreements with partners such as Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., the University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. Established in 2008, argenx SE's headquarters are located in Breda, the Netherlands.

Argenx to Buy Forte Biosciences for $2.2 Billion

2026-07-27 01:29:00

The deal to acquire the Nasdaq-listed Forte represents a 41% premium to its closing price on Friday.

Argenx to buy Forte Biosciences for about $2.2 billion

2026-07-27 01:15:45

Belgian-Dutch immunology company argenx ​will buy ‌Forte Biosciences to add experimental ​autoimmune drug ​FB102 to its portfolio, ⁠the company ​said on ​Monday.

Argenx's Vyvgart sales jump in second quarter

2026-07-23 01:41:31

Belgian-Dutch immunology company argenx said on ​Thursday global sales of its lead ‌drug Vyvgart jumped in the second quarter of 2026 from a year earlier.

Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit

2026-06-10 10:15:51

Sanofi scrapped a final-phase study Wednesday of an experimental CIDP treatment. The stock tumbled in response.

Frequently Asked Questions

What is the current argenx SE (ARGNF) stock price?

argenx SE(OTC:ARGNF) stock price is $865 in the last trading session. During the trading session, ARGNF stock reached the peak price of $960.58 while $547.6 was the lowest point it dropped to. The percentage change in ARGNF stock occurred in the recent session was 0.0% while the dollar amount for the price change in ARGNF stock was $0.

ARGNF's industry and sector of operation?

The OTC listed ARGNF is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of ARGNF?

Achim Plueckebaum | Global Head of Digital Technologies
Sandrine Piret-Gerard | Chief Commercialization Officer
Karl Gubitz | Chief Financial Officer
Timothy Van Hauwermeiren EMBA | Co-Founder & Non-Independent Non-Executive Chairman of the Board
Arjen Lemmen | Vice President of Corporate Development & Strategy

How many employees does ARGNF have?

Number of ARGNF employees currently stands at 1863. ARGNF operates from Laarderhoogtweg 25, Amsterdam, NH 1101 EB, NL.

Link for ARGNF official website?

Official Website of ARGNF is: http://www.argen-x.com

How do I contact ARGNF?

ARGNF could be contacted at phone #31 10 703 8441 and can also be accessed through its website. ARGNF operates from Laarderhoogtweg 25, Amsterdam, NH 1101 EB, NL.

How many shares of ARGNF are traded daily?

The average number of ARGNF shares traded daily for last 3 months was 11.

What is the market cap of ARGNF currently?

The market value of ARGNF currently stands at $53.79B with its latest stock price at $865